Sun Pharma Q2 FY27 Results: Net Profit Falls 36% to Rs 1,989 Crore on Rs 1,269 Crore One-Time Charges, While Adjusted Profit Rises 1.4% and Revenue Climbs 12%

Sun Pharma Q2 results for FY27 look alarming at first glance, because reported profit fell 36%. The detail is more nuanced: the drop is caused by one-time charges, and underlying profit and revenue grew. This Sun Pharma Q2 results analysis breaks down the numbers, what each business did, the share price reaction and what to watch.

The share price is as of 11:08 AM IST on 2 November 2026. Financials are from the company's results of Friday, 30 October 2026.

Click Here – Get Free Investment Predictions

Sun Pharma Q2 FY27 Results: Key Numbers

Metric	Q2 FY27	Q2 FY26	Change
Consolidated net profit	Rs 1,988.5 crore	Rs 3,118 crore	Down 36.2%
Adjusted net profit (before exceptionals)	Rs 3,162 crore	Not stated	Up 1.4%
Revenue from operations	Rs 16,198.7 crore	Rs 14,478.3 crore	Up 11.9%
Exceptional charges	Rs 1,268.8 crore	Not stated	One-time
EBITDA margin	29.3%	31.3%	Lower
US formulation sales	$455 million	Not stated	Down 8.2%
Global innovative medicines	$356 million	Not stated	Up 6.9%
India formulation sales	Not stated	Not stated	Up 17.3%
R&D spend	Rs 778.4 crore	Not stated	4.8% of sales

Source: Sun Pharma Q2 FY27 results, Business Standard, Moneycontrol, Upstox and InCred Money reports. Different reports round some figures slightly.

Why Did Sun Pharma's Profit Fall 36%?

The Sun Pharma profit decline is driven by exceptional charges of Rs 1,268.8 crore booked in the quarter, which include a US antitrust settlement and costs linked to the Organon acquisition. Excluding these items, adjusted net profit was Rs 3,162 crore, up 1.4%. Because one-time items do not recur, the market usually looks at the adjusted number, although the settlement and acquisition costs are real cash and strategic costs.

Business Performance: India, US and Innovative Medicines

In the Sun Pharma Q2 results, India formulation sales grew 17.3%, the strongest part of the quarter. US formulation sales fell 8.2% to $455 million, a drag on the margin and an area investors watch closely. Global innovative medicines grew 6.9% to $356 million and now make up 21.1% of sales, which supports Sun Pharma's shift toward specialty products. The company filed 4 ANDAs and received approval for 3 during the quarter.

Sun Pharma profit quality shows in margins: EBITDA margin was 29.3% against 31.3% a year earlier, which shows the cost of the US pressure and higher spending, even though EBITDA grew about 5% to Rs 4,743 crore.

Check the Univest Screener for pharma stocks and valuations

Sun Pharma Share Price Reaction

The Sun Pharma share price rose about 4% to Rs 1,833.30 in afternoon trade on 30 October after the results but closed at Rs 1,777.70, and is at Rs 1,769.90 today, down 0.44%. At this price Sun Pharma has a market cap of about Rs 4.27 lakh crore, a P/E of about 38.8 against an industry P/E of about 38.1, a return on equity of 13.79% and a dividend yield of 0.90%. The valuation is in line with the sector, so growth in the US and specialty portfolio has to justify it.

What to Watch Next for Sun Pharma

For the Sun Pharma share price, four things matter: whether US generic sales stabilise, how quickly specialty products scale, the integration cost and timeline of the Organon acquisition, and whether further legal settlements arise. Management commentary on the next two quarters will matter more than this quarter's reported profit.

Download the Univest iOS App or Univest Android App to follow Sun Pharma and pharma stocks on your watchlist.

Conclusion

Sun Pharma Q2 results show reported profit down 36% but adjusted profit up 1.4% and revenue up nearly 12%, with India strong and the US weak. The stock is priced in line with the sector, so the next trigger is evidence that specialty growth and the Organon deal can lift margins.

Frequently Asked Questions on Sun Pharma Q2 Results

What were Sun Pharma's Q2 FY27 results?

Ans. Sun Pharma reported consolidated net profit of Rs 1,988.5 crore, down 36.2% from Rs 3,117.95 crore, and revenue from operations of Rs 16,198.7 crore, up 11.9%. Adjusted net profit excluding exceptional items was Rs 3,162 crore, up 1.4%. EBITDA margin was 29.3% against 31.3% a year earlier.

Why did Sun Pharma's profit fall in Q2?

Ans. Profit fell because of exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and costs for the Organon acquisition. Without these one-time items, adjusted net profit rose 1.4% to Rs 3,162 crore. The settlement and acquisition costs are real, but they are not part of regular operating earnings.

How did Sun Pharma's US business perform?

Ans. US formulation sales fell 8.2% to $455 million in Q2 FY27. Pricing pressure on generics is a recurring issue, and the US is a key market for the company. Investors watch for stabilisation and for specialty product launches that can offset the decline in generics.

How did Sun Pharma's India business perform?

Ans. India formulation sales grew 17.3% in Q2 FY27, making it the strongest part of the quarter. Growth in chronic therapies and the strength of Sun's field force are typically cited drivers, but check the company's presentation for the specific breakdown by therapy.

What is Sun Pharma's share price today?

Ans. Sun Pharma traded at Rs 1,769.90 on the NSE at 11:08 AM IST on 2 November 2026, down Rs 7.80 or 0.44% from Rs 1,777.70. The day's range is Rs 1,722 to Rs 1,776.20. The market cap is about Rs 4.27 lakh crore.

What is the Organon acquisition?

Ans. Business Standard reported that Sun Pharma's exceptional charges include costs connected to the acquisition of Organon. Check Sun Pharma's stock exchange filings for the deal's size, structure and expected completion, as those details affect leverage, margins and the pace of its specialty business.

Is Sun Pharma stock valued fairly after the results?

Ans. At a P/E of about 38.8 against an industry P/E of about 38.1 and a return on equity of 13.79%, Sun Pharma is priced in line with its sector. Whether that is fair depends on specialty growth, US recovery and margin trends. Brokerage targets differ, so compare views before deciding.

Should I buy Sun Pharma after a profit fall?

Ans. A profit fall due to one-time items is different from an operating decline, but the US weakness and lower margin are real concerns. Review adjusted earnings, management guidance and valuation before buying, and stagger purchases. This is not investment advice, so consult a SEBI-registered advisor.